Rhumbline Advisers Boosts Holdings in Altimmune, Inc. (NASDAQ:ALT)

Rhumbline Advisers raised its holdings in Altimmune, Inc. (NASDAQ:ALT) by 25.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 107,446 shares of the company’s stock after purchasing an additional 22,034 shares during the period. Rhumbline Advisers owned 0.15% of Altimmune worth $715,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Farallon Capital Management LLC boosted its position in Altimmune by 1,282.4% during the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock worth $4,785,000 after acquiring an additional 436,000 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new position in shares of Altimmune in the 4th quarter worth about $4,493,000. Knoll Capital Management LLC increased its position in Altimmune by 183.6% during the 1st quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock worth $5,774,000 after purchasing an additional 367,219 shares in the last quarter. Gerber LLC purchased a new position in Altimmune in the fourth quarter valued at approximately $2,878,000. Finally, SG Americas Securities LLC increased its position in shares of Altimmune by 542.8% in the second quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after acquiring an additional 214,968 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Stock Performance

Shares of ALT opened at $7.12 on Wednesday. Altimmune, Inc. has a one year low of $2.09 and a one year high of $14.84. The stock has a 50-day moving average price of $6.68 and a 200 day moving average price of $7.34. The company has a market capitalization of $504.82 million, a P/E ratio of -4.48 and a beta of 0.08.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, August 8th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The business had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 24,778.97% and a negative return on equity of 53.09%. During the same period in the prior year, the business posted ($0.32) EPS. As a group, equities research analysts forecast that Altimmune, Inc. will post -0.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ALT has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Altimmune in a report on Thursday, August 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Altimmune in a research report on Friday, June 21st. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Finally, B. Riley restated a “buy” rating and issued a $20.00 price target on shares of Altimmune in a report on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.80.

Insider Buying and Selling at Altimmune

In related news, Director David Drutz sold 16,011 shares of Altimmune stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares in the company, valued at $289,510.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is currently owned by insiders.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.